Proof of concept nanotechnological approach to in vitro targeting of malignant melanoma for enhanced immune checkpoint inhibition

[1]  N. Gleeson,et al.  Ex vivo expansion of circulating tumour cells (CTCs) , 2023, Scientific Reports.

[2]  G. Kochan,et al.  Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events , 2023, Cancers.

[3]  Z. Tian,et al.  NADPH Selective Depletion Nanomedicine‐Mediated Radio‐Immunometabolism Regulation for Strengthening Anti‐PDL1 Therapy against TNBC , 2022, Advanced science.

[4]  O. Baffa,et al.  Uniform Size PEGylated Iron Oxide Nanoparticles as a Potential Theranostic Agent Synthesized by a Simple Optimized Coprecipitation Route , 2022, Journal of Magnetism and Magnetic Materials.

[5]  T. D. de Gruijl,et al.  From simplicity to complexity in current melanoma models , 2022, Experimental dermatology.

[6]  T. Zhao,et al.  BMS‐202, a PD‐1/PD‐L1 inhibitor, decelerates the pro‑fibrotic effects of fibroblasts derived from scar tissues via ERK and TGFβ1/Smad signaling pathways , 2022, Immunity, inflammation and disease.

[7]  V. Velcheti,et al.  Immunotherapy in non-small cell lung cancer: Past, present, and future directions , 2022, Frontiers in Oncology.

[8]  Revisiting checkpoint blockade , 2022, Nature Biotechnology.

[9]  Michael R Hamblin,et al.  An update on dual targeting strategy for cancer treatment. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Tingting Meng,et al.  Combination of tumor vessel normalization and immune checkpoint blockade for breast cancer treatment via multifunctional nanocomplexes. , 2022, Biomaterials science.

[11]  E. Saber,et al.  Metformin-loaded ethosomes with promoted anti-proliferative activity in melanoma cell line B16, and wound healing aptitude: Development, characterization and in vivo evaluation. , 2022, International journal of pharmaceutics.

[12]  Lanlan Shen,et al.  Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through "ring fusion" strategy. , 2022, Bioorganic chemistry.

[13]  F. Bray,et al.  Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. , 2022, JAMA dermatology.

[14]  M. Bros,et al.  Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses? , 2022, Cancers.

[15]  Bingjun Sun,et al.  Paclitaxel derivative-based liposomal nanoplatform for potentiated chemo-immunotherapy. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[16]  N. Tan,et al.  Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy , 2021, Acta pharmaceutica Sinica. B.

[17]  C. Genova,et al.  Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade , 2022, Frontiers in Immunology.

[18]  T. George,et al.  The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials , 2021, Frontiers in Oncology.

[19]  S. Ladoire,et al.  Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives , 2021, Cancers.

[20]  Prashanth Rawla,et al.  Epidemiology of Melanoma , 2021, Medical sciences.

[21]  E. Novellino,et al.  Interfering with the Tumor-Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 Inhibitors. , 2021, Journal of medicinal chemistry.

[22]  X. Guan,et al.  Thermal-sensitive lipid nanoparticles potentiate anti-PD therapy through enhancing drug penetration and T lymphocytes infiltration in metastatic tumor. , 2021, Cancer letters.

[23]  Yu Zheng,et al.  Adoptive CD8+T-cell grafted with liposomal immunotherapy drugs to counteract the immune suppressive tumor microenvironment and enhance therapy for melanoma. , 2021, Nanoscale.

[24]  Kyoung-Mee Kim,et al.  PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score , 2021, Cancers.

[25]  Xuesi Chen,et al.  Cisplatin Nanoparticles Possess Stronger Anti-tumor Synergy with PD1/PD-L1 Inhibitors than the Parental Drug. , 2021, Acta biomaterialia.

[26]  Karin M Torres-Obreque,et al.  Building better biobetters: from fundamentals to industrial application. , 2021, Drug discovery today.

[27]  Khaled S. Allemailem,et al.  Novel Approaches of Dysregulating Lysosome Functions in Cancer Cells by Specific Drugs and Its Nanoformulations: A Smart Approach of Modern Therapeutics , 2021, International journal of nanomedicine.

[28]  Takashi Nakamura,et al.  STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation , 2021, Journal for ImmunoTherapy of Cancer.

[29]  Yongheng Chen,et al.  Nanomaterials for cancer therapy: current progress and perspectives , 2021, Journal of Hematology & Oncology.

[30]  Yilun Liu,et al.  Molecular Targeted Agent and Immune Checkpoint Inhibitor Co-Loaded Thermosensitive Hydrogel for Synergistic Therapy of Rectal Cancer , 2021, Frontiers in Pharmacology.

[31]  Baolin Zhang,et al.  Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics , 2021, The AAPS Journal.

[32]  B. Dong,et al.  IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor , 2021, Nature Immunology.

[33]  D. DeNardo,et al.  Rethinking immune checkpoint blockade: ‘Beyond the T cell’ , 2021, Journal for ImmunoTherapy of Cancer.

[34]  P. Varamini,et al.  Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy. , 2020, Future oncology.

[35]  S. Botchway,et al.  Porous Carbon Microparticles as Vehicles for the Intracellular Delivery of Molecules , 2020, Frontiers in Chemistry.

[36]  Yoshimasa Tanaka,et al.  Synthesis and Evaluation of Biphenyl-1,2,3-Triazol-Benzonitrile Derivatives as PD-1/PD-L1 Inhibitors , 2020, ACS omega.

[37]  Y. Luan,et al.  Rational Design of a Robust Antibody-Like Small Molecule Inhibitor Nanoplatform for Enhanced Photoimmunotherapy. , 2020, ACS applied materials & interfaces.

[38]  Xiaole Shirley Liu,et al.  TIMER2.0 for analysis of tumor-infiltrating immune cells , 2020, Nucleic Acids Res..

[39]  T. Lüscher,et al.  Therapeutic Implications , 2020, The Endothelium: Modulator of Cardiovascular Function.

[40]  Zhengping Hu,et al.  PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice , 2020, PloS one.

[41]  M. Mingari,et al.  Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance? , 2020, Cancers.

[42]  Hongyang Wang,et al.  Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade , 2020, Frontiers in Immunology.

[43]  J. Wolchok,et al.  Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Egen,et al.  Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. , 2020, Immunity.

[45]  T. Ashizawa,et al.  Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. , 2019, Biomedical research.

[46]  R. Zhang,et al.  Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer. , 2019, Small.

[47]  P. Hegde,et al.  Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab , 2019, Clinical Cancer Research.

[48]  M. Eckstein,et al.  New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story? , 2019, Annals of translational medicine.

[49]  G. Bakker,et al.  The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture , 2019, bioRxiv.

[50]  R. Zeiser,et al.  Clinical implications of tumor-intrinsic mechanisms regulating PD-L1 , 2019, Science Translational Medicine.

[51]  P. Forde,et al.  PD-1 Blockade in Early-Stage Lung Cancer. , 2019, Annual review of medicine.

[52]  R. Najafi,et al.  PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy , 2018, Journal of cellular physiology.

[53]  P. Boya,et al.  Lysosomal membrane permeabilization and cell death , 2018, Traffic.

[54]  F. Treussart,et al.  Fluorescent Nanodiamond Applications for Cellular Process Sensing and Cell Tracking , 2018, Micromachines.

[55]  J. Rossjohn,et al.  Unconventional T Cell Targets for Cancer Immunotherapy. , 2018, Immunity.

[56]  T. Schumacher,et al.  Regulation and Function of the PD-L1 Checkpoint. , 2018, Immunity.

[57]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[58]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[59]  K. Zak,et al.  Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. , 2017, Structure.

[60]  T. Fu,et al.  Expression levels of cleaved caspase-3 and caspase-3 in tumorigenesis and prognosis of oral tongue squamous cell carcinoma , 2017, PloS one.

[61]  N. Prabhakar,et al.  Intracellular Trafficking of Fluorescent Nanodiamonds and Regulation of Their Cellular Toxicity , 2017, ACS omega.

[62]  A. Goodman,et al.  PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas , 2017, Nature Reviews Clinical Oncology.

[63]  K. He,et al.  FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma , 2017, Clinical Cancer Research.

[64]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[65]  Huanyu Chen,et al.  FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma , 2017, Clinical Cancer Research.

[66]  P. Keegan,et al.  U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab , 2017, Clinical Cancer Research.

[67]  R. Scolyer,et al.  Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.

[68]  K. Zak,et al.  Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) , 2016, Oncotarget.

[69]  M. Vicente-Manzanares.  Faculty of 1000 evaluation for Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. , 2016 .

[70]  A. P. Bell,et al.  Proinflammatory Effects of Pyrogenic and Precipitated Amorphous Silica Nanoparticles in Innate Immunity Cells. , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[71]  B. Dörken,et al.  Myeloid-derived suppressor cells in human peripheral blood: Optimized quantification in healthy donors and patients with metastatic renal cell carcinoma. , 2015, Immunology letters.

[72]  Lu Tian,et al.  Nanodiamond-conjugated transferrin as chemotherapeutic drug delivery , 2015 .

[73]  David M. Woods,et al.  HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade , 2015, Cancer Immunology Research.

[74]  J. Schlom,et al.  PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients , 2014, Journal of Immunotherapy for Cancer.

[75]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[76]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Haijun Yu,et al.  Nanodiamonds-mediated doxorubicin nuclear delivery to inhibit lung metastasis of breast cancer. , 2013, Biomaterials.

[78]  Giuseppe Schettino,et al.  Use of the γ-H2AX Assay to Investigate DNA Repair Dynamics Following Multiple Radiation Exposures , 2013, PloS one.

[79]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[80]  Dongxin Wang,et al.  PEGylated nanodiamond for chemotherapeutic drug delivery , 2013 .

[81]  David R McIlwain,et al.  Caspase functions in cell death and disease. , 2013, Cold Spring Harbor perspectives in biology.

[82]  A. Prina‐Mello,et al.  Citrullination as early-stage indicator of cell response to Single-Walled Carbon Nanotubes , 2013, Scientific Reports.

[83]  D. Firsanov,et al.  Dynamics of γH2AX formation and elimination in mammalian cells after X-irradiation. , 2012, Biochimie.

[84]  H. Man,et al.  Diamond as a nanomedical agent for versatile applications in drug delivery, imaging, and sensing , 2012 .

[85]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[86]  C. Drake,et al.  Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma , 2011, Clinical Cancer Research.

[87]  Shengbing Huang,et al.  The Role of Autophagy in Cancer: Therapeutic Implications , 2011, Molecular Cancer Therapeutics.

[88]  Dermot Kelleher,et al.  Activation of stress-related signalling pathway in human cells upon SiO2 nanoparticles exposure as an early indicator of cytotoxicity , 2011, Journal of nanobiotechnology.

[89]  K. O'Byrne,et al.  Receptor tyrosine kinases and their activation in melanoma , 2011, Pigment cell & melanoma research.

[90]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[91]  H. Chung,et al.  Nanomaterials for cancer therapy and imaging , 2011, Molecules and cells.

[92]  A. Korman,et al.  Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. , 2010, Seminars in oncology.

[93]  G. Kroemer,et al.  Lysosomal membrane permeabilization in cell death , 2008, Oncogene.

[94]  Chenjie Xu,et al.  Controlled PEGylation of Monodisperse Fe3O4 Nanoparticles for Reduced Non‐Specific Uptake by Macrophage Cells , 2007 .

[95]  V. Natale,et al.  H2AX phosphorylation within the G1 phase after UV irradiation depends on nucleotide excision repair and not DNA double-strand breaks. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[96]  G. Collins.  The next generation. , 2006, Scientific American.

[97]  E. Rogakou,et al.  Quantitative Detection of 125IdU-Induced DNA Double-Strand Breaks with γ-H2AX Antibody , 2002 .

[98]  R. Hendrick.  Review of clinical trials , 2002, Breast Cancer Research.

[99]  E. Rogakou,et al.  Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. , 2002, Radiation research.

[100]  Jennifer L. Dornan.  Past , Present , and Future Directions , 2002 .

[101]  R. Schreiber,et al.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.

[102]  K. Öllinger,et al.  Cellular injury induced by oxidative stress is mediated through lysosomal damage. , 1995, Free radical biology & medicine.

[103]  E. Montserrat.  [The never ending story]. , 1995, Medicina clinica.

[104]  E Griffiths,et al.  Cell killing by lysosomotropic detergents , 1983, The Journal of cell biology.